Vera Therapeutics’ Trutakna meets all prespecified endpoints in ORIGIN 3 IgA nephropathy trial
Bitget2026/10/22 14:05- Vera Therapeutics reported positive final ORIGIN 3 trial results for Trutakna in adults with primary IgA nephropathy.
- The treatment met all prespecified efficacy endpoints, slowing kidney function decline and reducing the risk of kidney disease progression versus placebo.
- Safety was generally comparable to placebo, with fewer serious adverse events.
- Results were presented at ASN Kidney Week 2026 on October 22 and simultaneously published in The New England Journal of Medicine.
- A supplemental biologics license application is planned for the fourth quarter of 2026, with potential full FDA approval in 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
DoubleLine Capital: Large-Scale Borrowing and Weak Demand Will Continue to Put Pressure, Still Bearish on Long-Term U.S. Treasuries
DoubleLine Capital Deputy Chief Investment Officer Jeffrey Sherman stated that he remains bearish on long-term U.S. Treasury bonds, believing that large-scale government borrowing and weak demand will continue to put pressure on the U.S. Treasury market.
Report: SK Hynix abandons Solidigm US IPO plan
Solidigm originated from SK Hynix’s acquisition of Intel’s NAND flash and SSD business. Lee Chan-jin, Chairman of Korea’s Financial Supervisory Service, stated that Solidigm’s listing in the U.S. could be subject to Korea’s duplicate listing regulations. Previous reports indicated that Solidigm is considering going public on Nasdaq as early as 2027, with a potential valuation of up to 150 billions of dollars.
Elon Musk accelerates the creation of the "fourth largest U.S. carrier"! SpaceX (SPCX.US) plans to acquire 80,000 cellular base stations, offering new opportunities for communication tower companies
According to sources familiar with the matter, SpaceX plans to acquire at least 80,000 cellular base station sites in the United States and is currently in negotiations with at least one major cellular infrastructure company to achieve this goal.
Crypto prices
More
